DocuGuru
Springer Nature

Investigational New Drugs Template

Write in a clean editor, then format for Investigational New Drugs in one click — DocuGuru applies the official Springer Nature template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

Use this template

About the Investigational New Drugs format

Investigational New Drugs is a peer-reviewed journal published by Springer Nature, covering Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms, Lung Cancer Treatments and Mutations.

PublisherSpringer Nature
Reference styleNumbered (Springer Basic)
Numbered — [1], [2] in the text
1. Smith A, Jones B, Lee C (2023) A representative article title. Investigational New Drugs 12:45–58

Formats any DOI in Investigational New Drugs style. No sign-up.

Publishes research inCancer Treatment and Pharmacology Cancer therapeutics and mechanisms Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Lung Cancer Research Studies
ISSN0167-6997
Citation impact (2-yr)3.67
h-index115
i10-index2,514
Total citations108,153
Article processing charge$4,390
Top institutions publishing hereThe University of Texas MD Anderson Cancer Center
Journal websitewww.springer.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Investigational New Drugs per year

143
2014
118
2015
99
2016
136
2017
158
2018
177
2019
146
2020
165
2021
123
2022
91
2023
74
2024
101
2025

Citation impact of Investigational New Drugs by publication year

5.9K
2014
3.9K
2015
3.5K
2016
4.3K
2017
3.8K
2018
4.5K
2019
2.9K
2020
2.8K
2021
1.4K
2022
625
2023
487
2024
251
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Investigational New Drugs

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · 12 Jun 2014

The G1 restriction point is critical for regulating the cell cycle and is controlled by the Rb pathway (CDK4/6-cyclin D1-Rb-p16/ink4a). This pathway is important because of its inactivation in a majority of human tumors. Transition through the restriction point requires phosphorylation of retinoblastoma protein (Rb) by CDK4/6, which are highly validated cancer drug targets. We…

568 citations Cite SaveGo to paper →

Investigational New Drugs template — frequently asked questions

How do I write a paper in the Investigational New Drugs format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Investigational New Drugs template. When you export, DocuGuru compiles the paper into the official Springer Nature format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Investigational New Drugs use?
Investigational New Drugs uses Numbered (Springer Basic) references, shown as numbered [1], [2] markers in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: 1. Smith A, Jones B, Lee C (2023) A representative article title. Investigational New Drugs 12:45–58
Do I need to know LaTeX to submit to Investigational New Drugs?
No. DocuGuru generates the sn-jnl LaTeX class and compiles the PDF for you in the background, so you get a Springer Nature-ready Investigational New Drugs document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Investigational New Drugs template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Investigational New Drugs format with correct headings, figures, tables, and numbered citations.
Who publishes Investigational New Drugs?
Investigational New Drugs is a multidisciplinary journal published by Springer Nature. DocuGuru's Investigational New Drugs template matches Springer Nature's official submission format.
Can I export a submission-ready Investigational New Drugs PDF?
Yes — DocuGuru produces a PDF built with the official Investigational New Drugs template (the sn-jnl class) that is ready to submit to Springer Nature, together with the matching LaTeX source files.
How much does the Investigational New Drugs template cost?
You can start writing in the Investigational New Drugs template for free. Exporting the final submission-ready Investigational New Drugs PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Investigational New Drugs template